JOHNSON & JOHNSON

For the period ended Dec 28, 2025. Filed Feb 11, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 11, 2026

JNJ$280.78-0.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated statements of earnings

Johnson & Johnson and subsidiaries consolidated statements of earnings

(Dollars and Shares in Millions Except Per Share Amounts) (Note 1)

	2025	2024	2023
Sales to customers	$94,193	88,821	85,159
Cost of products sold	30,256	27,471	26,553
Gross profit	63,937	61,350	58,606
Selling, marketing and administrative expenses	23,676	22,869	21,512
Research and development expense	14,665	17,232	15,085
In-process research and development impairments	81	211	313
Interest income	(1,056)	(1,332)	(1,261)
Interest expense, net of portion capitalized (Note 4)	971	755	772
Other (income) expense, net	(7,209)	4,694	6,634
Restructuring (Note 20)	228	234	489
Earnings before provision for taxes on income	32,581	16,687	15,062
Provision for taxes on income (Note 8)	5,777	2,621	1,736
Net earnings from continuing operations	26,804	14,066	13,326
Net earnings from discontinued operations, net of tax (Note 21)	—	—	21,827
Net earnings	$26,804	14,066	35,153
Net earnings per share (Notes 1 and 15)
Continuing operations - basic	$11.13	5.84	5.26
Discontinued operations - basic	—	—	8.62
Total net earnings per share - basic	$11.13	5.84	13.88
Continuing operations - diluted	$11.03	5.79	5.20
Discontinued operations - diluted	—	—	8.52
Total net earnings per share - diluted	$11.03	5.79	13.72
Average shares outstanding (Notes 1 and 15)
Basic	2,407.4	2,407.3	2,533.5
Diluted	2,429.4	2,429.4	2,560.4

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.